SCHEDULE 13G 0001453072 XXXXXXXX LIVE Common Stock, par value $0.0001per share 12/31/2025 0002006986 Adagio Medical Holdings, Inc. 00534B100 26051 Merit Circle Suite 102 Laguna Hills CA 92653 Rule 13d-1(b) Alyeska Investment Group, L.P. DE 0.00 2096784.00 0.00 2096784.00 2096784.00 N 9.9 IA Alyeska Fund GP, LLC DE 0.00 2096784.00 0.00 2096784.00 2096784.00 N 9.9 OO Anand Parekh X1 0.00 2096784.00 0.00 2096784.00 2096784.00 N 9.9 IN Adagio Medical Holdings, Inc. 26051 Merit Circle, Suite 102, Laguna Hills, CA 92653 (i) Alyeska Investment Group, L.P. (ii) Alyeska Fund GP, LLC (iii) Anand Parekh (i) 77 West Wacker Drive, 7th Floor, Chicago, IL 60601 (ii) 77 West Wacker Drive, 7th Floor, Chicago, IL 60601 (iii) 77 West Wacker Drive, 7th Floor, Chicago, IL 60601 (i) Alyeska Investment Group, L.P. - Delaware (ii) Alyeska Fund GP, LLC - Delaware (iii) Anand Parekh - United States of America N IA HC 2,096,784 9.9% 0 2,096,784 0 2,096,784 Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. The reporting persons are the beneficial owners of 1,159,615 common PIPE shares of the Issuer and hold warrants to purchase 2,136,177 shares of the Issuer's Class A common stock, (the "Warrants"). However, per their terms, the Warrants can only be exercised into such number of shares that would constitute 9.9% of the total number of Common Stock of the Issuer outstanding immediately after giving effect to the issuance of Common Stock upon exercise of this Warrant by the Holder. Accordingly, as of December 31, 2025 the reporting persons may only exercise up to 937,169 Ordinary Shares under the Warrant Agreement, and as such, is reporting beneficial ownership of only such number of shares. The percentage calculation assumes that there are currently 21,179,637 outstanding shares of Ordinary Shares of the Issuer, based on the Issuer's Prospectus filed with the Securities and Exchange Commission on December 16, 2025. JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Alyeska Investment Group, L.P. Jason Bragg 02/17/2026 Alyeska Fund GP, LLC Jason Bragg 02/17/2026 Anand Parekh Anand Parekh 02/17/2026